65,437 trials
Pancreatic Carcinoma Non-resectable · Metastatic Pancreatic Cancer
Primary: To Determine the Dose Limiting Toxicities — 27 participants
Alveolar Bone Loss · Loss of Teeth Due to Extraction · Edentulous Alveolar Ridge
Primary: Change in Bone Gain or Loss in Millimeters (Buccopalatal) — 7.7 mm
Mild Cognitive Impairment
Primary: Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI — 5.87; 8.14; 6.26; 7.08 percent change per participant year
Asthma
Primary: Number of Subjects With Adverse Events — 0; 0; 0; 0 participants
Anemia
Primary: Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15 — 0.69; 0.10 g/m^2 — p=0.8811
Food Hypersensitivity · Milk Hypersensitivity
Primary: Number of Participants With a Positive Progression in Tolerance of Baked Milk and Ultimately Unheated Milk in Dose Escalation Sub-arm Compared to Maintenance Sub-arm…
Sanfilippo Syndrome Type A
Primary: Change From Baseline in Bayley Scales of Infant Development-III/Kaufman Assessment Battery for Children-II (BSID-III/KABC-II) Age-Equivalent Scores — 0.17; 1.19; -1.72…
Metastatic Colorectal Cancer
Primary: Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) — 0; 0; 0; 0 subjects
Sleep Disorders
Primary: Change in Pittsburgh Sleep Quality Index — -0.86; -3.15; -3.32 difference score of PSQI total
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC 0-t) — 1490.0; 1273.0 h*ng/mL
Chronic Renal Anemia
Primary: Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)…
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Patients With Adverse Events, Serious Adverse Events, and Death — 26; 25; 24; 139 Number of Patients
Dental Plaque · Gingivitis
Primary: Dental Plaque Scores — 3.91; 3.86; 3.84 units on a scale — p=0.652
COPD · Healthy Subjects
Primary: Adverse Events — 6; 3; 7; 2 Participants